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•

Characterize the use and assess the efficacy of tolvaptan and
urea in the treatment of patients who were admitted to the
hospital with chronic hyponatremia.

BACKGROUND
• Hyponatremia is one of the most common electrolyte disorders,
occurring in 15-30% of patients who are hospitalized.1 Severe
hyponatremia may result in headaches, altered mental status,
seizure, and coma.2
• Chronic hyponatremia is hyponatremia lasting longer than 48 hours.2
• Treatment strategies for hyponatremia include fluid restriction,
hypertonic saline infusion, sodium tablets, vasopressin receptor
antagonists, and urea.2
• In chronic hyponatremia, the maximum correction rate of serum
sodium is 8 to 10 mEq/L within the first 24 hours of treatment to
reduce the risk of developing osmotic demyelination of cells.1,3
• In severe symptomatic hyponatremia, recommendations allow for up
to 12 mEq/L correction within the first 24 hours and a total of 18
mEq/L within the first 48 hours.3
• Syndrome of inappropriate anti-diuretic hormone (SIADH), is a
common cause of chronic hyponatremia.4
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Table 1 – Subject demographics

Male
Average Age (years)
Liver Dysfunction at Baseline
Hyponatremia Status
Mild Hyponatremia
Moderate Hyponatremia
Severe Hyponatremia
No Hyponatremia
Received Prior Treatments
Normal Saline
Fluid Restriction
Sodium Tablets
Hypertonic Saline
Loop Diuretics
PTA Hyponatremia Treatment
Urea
Salt Tablets

Tolvaptan
N=68
39
69
8

Urea
N=225
98
70
21

Both
N=21
8
69.1
1

Total
N=314
145
69.7
30

1
48
18
1

31
150
34
10

1
15
5
0

33
213
57
11

29
16
33
18
36

90
53
92
30
81

10
8
9
3
9

129
77
134
51
126

0
2

13
21

1
4

14
27

Figure 1 – Contributory PTA
medications (N=314)
None

One

Multiple

• Common medication classes may contribute to hyponatremia; these
include selective serotonin receptor inhibitors (SSRIs), serotoninnorepinephrine receptor inhibitors (SNRIs), and anticonvulsants.

METHODS
• Retrospective analysis conducted within 2 community hospitals
• This analysis was approved by the Institutional Review Board.
• Inclusion criteria:
• Admission between January 1, 2020 through December 31, 2021
• Patients aged 18 or older and having received at least one dose of
tolvaptan and/or urea during admission
• Hyponatremia severity was classified via serum sodium levels
measured within 24 hours prior to initiation of tolvaptan or urea5
• Mild: serum sodium 130 to 134 mEq/L
• Moderate: serum sodium 120 to 129 mEq/L
• Severe: serum sodium less than 120 mEq/L
• Baseline labs were collected to assess liver function
• Liver dysfunction was defined as aspartate aminotransferase
(AST), alanine transaminase (ALT), or total bilirubin more than
three times the upper limit of normal
• Patients were analyzed based on subjective and objective diagnosis
of SIADH, and prior to admission (PTA) prescriptions were reviewed
for any potential contributing medications
• Sodium change was defined as the difference from baseline serum
level, and measured serum level 24 +/- 4 hours after first dose of
either tolvaptan or urea.

23.6%
34.4%

42%

Table 2 – Change in 24-hour serum sodium with corrective measures
Tolvaptan Urea Both Total
N=68
N=225 N=21 N=314
Change in Baseline Serum Sodium
Levels (mEq/L)
Less than 0
6
18
4
28
1 to 5
11
71
3
85
6 to 10
20
38
8
66
11+
11
8
1
20
Unable To Calculate (UTC)
20
90
5
115
Received dextrose 5% in water
13
17
5
35
Received desmopressin
1
1
0
2
Received dextrose 5% in water and
desmopressin
4
6
0
10

• Out of the 314 unique encounters, 68 patients received tolvaptan, 225
patients received urea, and 21 received both during their admission.
• Objectively, 178 patients were found to qualify for SIADH diagnosis, but
only 123 were subjectively diagnosed via provider notes and diagnosis
codes.
• Patients receiving tolvaptan were more likely to have increases in serum
sodium by greater than 10 mEq/L in the first 24 hours (16.2%) as
compared to urea (3.5%).
• Average duration of therapy varied between treatment groups at 1.7
days and 2.6 days for tolvaptan and urea, respectively.
Table 3 – Average 24-hour change in serum sodium (mEq/L) based on severity
Mild Hyponatremia
Moderate Hyponatremia
Severe Hyponatremia

Tolvaptan
UTC
7.4
7.9

Urea
0.7
3.7
7.5

Both
-1
4.3
7.25

DISCUSSION & CONCLUSIONS
• Within the first 24 hours following administration, urea and tolvaptan
were both satisfactory in improving serum sodium levels.
• A majority of patients were taking medicines that may contribute to
hyponatremia; this is something that should always be assessed if a
patient is presenting with hyponatremia.
• Only 14.9% patients who received tolvaptan, urea, or both medicines
required corrective treatments due to a rapid serum sodium rise.
• Providers should exercise caution when using tolvaptan, as it was
associated with a higher risk of rapid serum sodium correction.
• Limitations:
• Many (36.6%) patients were not assessed, as they did not have
follow-up labs drawn within the 24-hour post-initial administration
window.
• Patients may have received varying treatments in addition to those
assessed, which may allow for differences in improvement of serum
sodium levels.
• Based on rate of improvement in serum sodium levels, it would be
appropriate to use either urea, tolvaptan, or both with additional
corrective measures and close monitoring for patients with severe
hyponatremia.
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